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Quantiﬁcation of sexual HIV transmission risk in Africa
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal home page: www.elsevier .com/ locat e/ i j idIn this issue of the journal, Awad et al. (2018) report concerning
a high (10%) annual HIV transmission risk between sexual
serodiscordant couples across 23 sub-Saharan African countries,
and further report a strong correlation of this risk with the HIV
prevalence within each of the countries.
HIV remains a major global public health threat, with around
2 million new infections per year (UNAIDS DATA, 2017). Although
antiretroviral therapy (ART) has scaled up and is now accessed by
more than 18 million persons globally, there remain at least 20
million person still untreated. ART not only reduces risk of
morbidity and mortality from HIV (Danel et al., 2015; Lundgren
et al., 2015), but if fully effective will also substantially reduce
risk of onward transmission by any route including sexual,
mother-to-child, or persons sharing needles (Cohen et al., 2016;
Rodger et al., 2016). The HIV epicentre was in Africa, and it is also
on this continent that the largest number of infected persons
lives.
The key determinant of risk of sexual transmission of HIV is the
amount of virus replicating in the already-infected person. The
viral replication rate is inﬂuenced by viral factors (some replicate
more rapidly than others), by host genomic factors (in particular
the HLA type), and by ART. Importantly, it is now well established
for heterosexual couples that as long as the index person is
receiving ART, and as long as the ART is fully effective in controlling
replication, the risk of transmission – even condom-less – is close
to zero (Rodger et al., 2016). This strong preventive effect of ART is
seen also in populations where other sexually transmitted diseases
occurs relatively frequently (Cohen et al., 2016). Recent data also
suggest that this protective effect can be extended to condomless
anal sex, which otherwise would carry an approximately 3-fold
higher risk of transmission compared with vaginal sex (Cohen
et al., 2016; Rodger et al., 2016).
The mode by Awad et al. (2018) supposedly takes ART coverage
in the population (i.e. % of infected persons on ART) into account,
and assumes that the protective effect from ART is 96%. This
number is reasonable derived from a large randomised controlled
trial (HPTN 052 (Cohen et al., 2016)). However, the key determi-
nant of the effect from ART is the extent that the therapy is able to
fully control viral replication or not. In HPTN 052 (Cohen et al.,
2016), a total of 8 linked transmissions were observed after the
index person had started ART, but all were linked to situations
where replication was either not yet fully controlled or had
rebounded because of variable adherence. Future work should
therefore incorporate ART coverage and rate of full suppressionhttps://doi.org/10.1016/j.ijid.2017.11.001
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prevalence. When done, it is projected that these parameters will
equally strongly correlate with risk of sexual transmission. In
sexual relationships where the already-infected person is on fully
suppressive ART, the risk will be expected to be close to nil.
Given that we do not have an effective HIV vaccine, control of the
future evolution is based on behavioural and medical preventive
strategies. Of these, the medical strategies are being focused on, as
modiﬁcation of sexual behaviour is most often ineffective.
So how do we further improve medical preventive strategies?
Use of ART to prevent transmission of course requires that the
person is diagnosed, and many of those not currently on ART are
not yet diagnosed. As such, scaling up testing and linkage to ART
care is central; in settings where this has been done, HIV
diagnosis rates are now starting to decrease (Brown et al., 2017).
The not yet infected persons have several options to protect
themselves from infection. These include use of condoms,
although multiple cultural, social and personal factors reduce
their public health impact. A new concept is use of pre-exposure
prophylaxis (PrEP) by use of one or two of the medicines used as
part of ART. WHO in 2015 recommended broad use of this strategy
(WHO, 2017). If used consistently (daily use is required to protect
women from vaginal exposure and trice weekly for persons
practising anal sex), this reduces risk by 70–90%. Finally,
uninfected men can be circumcised — as this reduces their risk
of infection by sex by approximately 50%. Given the invasive
nature of this intervention, it is likely only reasonable to
recommend in high prevalence countries.
WHO and UNAIDS have a shared vision of controlling HIV
transmission by 2020. This is technically possible and supported
by solid evidence. However, it will only happen if there is broad
commitment by all relevant stakeholders (primarily policy
makers and funders) to ensure unlimited access to HIV testing,
ART and PREP. It will be important to continue to monitor
progress by use of models exempliﬁed by the report from Awad
et al. (2018).
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